AstraZeneca PLC (AZN)vsHinge Health, Inc. (HNGE)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
HNGE
Hinge Health, Inc.
$43.99
-1.68%
HEALTHCARE · Cap: $3.46B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9892% more annual revenue ($58.74B vs $587.86M). AZN leads profitability with a 17.4% profit margin vs -89.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HNGE
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+16.0%
Fair Value
$46.15
Current Price
$43.99
$2.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 45.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 19.5x book value
Weak financial health signals
ROE of -132.9% — below average capital efficiency
Earnings declined 80.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : HNGE
The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : HNGE
The primary concerns for HNGE are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while HNGE is a hypergrowth play — different risk/reward profiles.
HNGE is growing revenue faster at 45.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.4% margins. HNGE offers better value entry with a 16.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Hinge Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?